surmount 1 tirzepatide lowers body weight for adults with obesity, regardless of disease duration Tirzepatide: the SURMOUNT-1 trial by

patients per year, requiring only safety demonstration (not efficacy) with streamlined review and $6,375 in user fees

Common Side Effects Facial flushing or warmth Nausea, stomach discomfort Chest tightness or pressure (usually dose/rate dependent) Headache Fatigue after administration Injection site discomfort, redness, or swelling Mild dizziness Seek Medical Attention For Severe chest pain or difficulty breathing Signs of allergic reaction: hives, facial swelling, throat tightness Fainting or severe dizziness Use in Pregnancy and Breastfeeding The safety of NAD+ therapy during pregnancy and breastfeeding has not been established

March 15, 2022 Some probiotics have been shown to modestly lower high cholesterol levels

For injectable medications, bioavailability is generally high (close to 100% for subcutaneous injections) because the drug is delivered directly into tissue without needing to pass through the gastrointestinal tract or first-pass metabolism

Four individual GLP-1 receptor agonists have now demonstrated MACE superiority in their dedicated cardiovascular outcome trials: Liraglutide: LEADER trial Semaglutide: SUSTAIN-6 and the landmark SELECT trial Dulaglutide: REWIND trial Albiglutide: HARMONY trial The SELECT trial deserves special attention because it broke entirely new ground

Cell 169 , 1276-1290 e1217